tbuckley/cabot-search huggingface dataset:
Anatomic features in victims of sudden coronary death. Coronary artery pathology.
Authors: Davies Mj
Journal: Circulation (1992)

Study of the detailed pathology of the myocardium and coronary arteries in ambulatory subjects dying suddenly of coronary heart disease shows that they can be divided into two groups. In one group, there is atherosclerosis with a new vascular event involving coronary thrombosis, which initiates acute myocardial ischemia. In the other group, there is chronic high-grade stenosis due to atherosclerosis, but there is no recent vascular change; the myocardium in this group shows scarring from a previously healed infarction acting as a substrate for reentrant ventricular arrhythmias. A study of 168 consecutive cases of sudden coronary death in London showed 73.3% to have had a recent coronary thrombotic lesion, giving a ratio of 2.7:1 for patients with versus patients without new acute myocardial ischemia. The widely differing ratios reported in the literature probably reflect the patterns of case selection. Prodromal pain immediately before the onset of ventricular fibrillation in a patient without previous known coronary disease selects for a thrombotic cause and acute myocardial ischemia. Absence of pain in a patient known to have had a previous infarction selects for a primary arrhythmia on the basis of preexisting myocardial hypertrophy and/or scarring.
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer according to body mass index
Authors: A. Gevorgyan, M. Ganzinelli, A. Martinetti, S. Lo Vullo, L. Mariani, F. Festinese, E. Sottotetti, B. Ferrari, G. Galli, F. de Braud, S. Di Cosimo
Journal: Annals of Oncology (2015)
OP0102 Genetic Effects on Trabecular and Cortical Volumetric Bone Mineral Densities and Bone Microstructure Measured by Hrpqct
Authors: F. Pan, K. Squibb, R. Thomson, T. Winzenberg, R. Zebaze, G. Jones
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> While both genetic and environmental factors affect areal BMD (aBMD), as much as 80% of variation in BMD is attributable to genetic factors [1]. aBMD measured by dual x-ray absorptiometry (DXA) is used as a surrogate measure for bone strength and is the gold standard for diagnosis of osteoporosis. However, structural abnormalities independent of aBMD may contribute to bone fragility. Bone structural parameters quantified using high-resolution pQCT (HRpQCT) may help more accurately identify individuals at risk for fracture than aBMD alone [2]. The heritability of cortical and/or trabecular bone microstructure determined by HRpQCT are unknown. <h3>Objectives</h3> To estimate heritability of trabecular density (TD), cortical density (CD), trabecular thickness (TT) and cortical thickness (CT) at tibia and radius measured by HRpQCT and investigate the genetic correlations of these between the tibia and radius. <h3>Methods</h3> Participants were 174 mother-child pairs from 161 families (161 mothers, mean age 52 years; 174 children, mean age 26 years). Cortical and trabecular bone microstructure at tibia and radius were measured by HRpQCT. SOLAR software was used to conduct quantitative genetic analyses with adjustment for covariates. <h3>Results</h3> In multivariable analysis, maternal tibial TD, CD, TT and CT were independently associated with all corresponding bone microstructures in the children (β=0.14 to 0.37, all P&lt;0.05) after adjustment for age, sex, weight, height, smoking history and physical activity. Additive genetic factors explained 67%, 36%, 33% and 46% of the variation in TD, CD, TT and CT, respectively (adjusted P&lt;0.05). Similar results were observed at the radius, but the heritability estimates were lower than that at tibia (range, 12%&gt;57%). Genetic correlations for TD and TT between tibia and radius (r<sub>g</sub>=0.80 for TD; 0.86 for TT) were greater than that of CD and CT (r<sub>g</sub>=0.47 for CD; 0.50 for CT). <h3>Conclusions</h3> Genetic factors appear to have an important role in the development of peak bone microarchitecture and are partly shared for the tibia and radius. The heritability estimates of radius were lower than that of tibia, suggesting tibia is affected by environmental factors to a greater extent than radius, possibly due to more loading at tibia. <h3>References</h3> Peacock M, Turner CH, Econs MJ, Foroud T: Genetics of osteoporosis. Endocr Rev 2002; 23:303–26. Zheng HF, Tobias JH, Duncan E, Evans DM, Eriksson J, Paternoster L et al: WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet 2012; 8:e1002745. <h3>Disclosure of Interest</h3> None declared
AB0248 Circulating Cell Free DNA; A Marker To Predict The Therapeutic Response for Biological Dmards in Rheumatoid Arthritis
Authors: T. Hasimoto, K. Yoshida, N. Hashimoto, K. Kaneshiro, A. Nakai, Y. Kawasaki, A. Hashiramoto
Journal: Annals of the Rheumatic Diseases (2016)

Background  DNA is fragmented and released into blood circulation as results of damage or death of cells from peripheral bloods as well as organ tissues, and circulating cell-free DNA (ccfDNA) has been recognized as biomarkers of several medical conditions [1]. In patients with rheumatoid arthritis (RA), serum concentration of ccfDNA has been reported to be elevated [2], however, the relation between ccfDNA and the pathogenesis of RA remains unclear.  Objectives  To evaluate the correlation between ccfDNA in plasma and clinical disease activities in patients with RA.  Methods  The study group included 29 patients with RA who started biological DMARDs therapy. The concentration of ccfDNA in plasma was measured by quantitative real-time PCR at baseline to 24 weeks in every 4 weeks-period from 29 patients, and 21 healthy individuals. We also evaluated the correlation between ccfDNA and the clinical activities or the response for biological DMARDs, using disease activity score of 28 joints erythrocyte sedimentation rate (DAS28ESR) and the european league against rheumatism (EULAR) response criteria. In addition, synovial fluid samples of knee joint were collected from 14 patients with RA and12 with osteoarthritis (OA) to measure ccfDNA  Results  The concentration of ccfDNA in RA patients at baseline was higher than healthy controls (p=0.016).When evaluated the concentration of ccfDNA, it was increased until 8 weeks-period from the baseline, and then decreased after 12weeks-period. The average of DAS28ESR was improved in all patients enrolled. At 12weeks-period after treatment, 15 patients were good responders of the EULAR response criteria, 9 showed the moderate response and 5 showed no response. The concentration of ccfDNA in good responder was increased until 8weeks while those of moderate or no responder were not (P=0.042) (figure), and there was no significant difference between ccfDNA at baseline and other parameters in all patients. In joint fluid of RA patients, the concentration of ccfDNA was remarkably increased as compared to those from OA (P=0.00011).  Conclusions  Increase of ccfDNA at 8 weeks-period was associated with improvement of disease activity. Compared with the biomarkers reported before, ccfDNA is possible to predict the early therapeutic effects of biological DMARDs in RA patients.  References  Jiajia Y, Guohao G, Shaoqing J. Recent Advances in Clinical Applications of Circulating Cell-free DNA Integrity. Lab medicine 2014;45:6–12  Zhong XY, Muhlenen IV, Li Y, Kang A, Gupta AK, Tyndall A, et al. Increased Concentrations of Antibody-Bound circulatory cell-free DNA in rheumatoid arthritis. Clin Chem 2007;53:1609–1614  Disclosure of Interest  None declared
Syk Inhibition By TAK-659 Overcomes Proliferative, Survival and Migratory Signals from the Microenvironment in Chronic Lymphocytic Leukemia Cells
Authors: Noelia Purroy, Pau Abrisqueta, Júlia Carabia, Eva Calpe, Cecilia Carpio, Carles Palacio, Marta Crespo, Francesc Bosch
Journal: Blood (2014)
OP0169 Association between Use of Disease-Modifying Anti-Rheumatic Drugs and Diabetes in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, or Psoriasis/psoriatic Arthritis: Nationwide, Population-Based Cohort Study of 84,989 Patients: Table 1.
Authors: H.-H. Chen, C.-C. Lin, Y.-M. Chen, K.-L. Lai, C.-H. Lin, D.-Y. Chen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Previous studies suggested anti-tumor necrosis factor (TNF) agents and hydroxychloroquine (HCQ) may inhibit the development of insulin resistance. <h3>Objectives</h3> Investigate the association between use of disease-modifying antirheumatic drugs (DMARDs) and diabetes mellitus (DM) in patients with ankylosing spondylitis (AS), rheumatoid arthritis (RA), or psoriasis (PSO)/psoriatic arthritis (PSA). <h3>Methods</h3> This retrospective cohort study used a nationwide, population-based administrative database to enroll 84,989 cases with AS, RA, or PSO/PSA who initiated treatment with anti-TNFs or nonbiologic DMARDs. Multivariable analysis was used to estimate effect of different therapies on risk of DM. <h3>Results</h3> There were 36,329 patients with AS, 33,112 patients with RA, and 15,638 patients with PS or PSA. All enrolled patients initiated treatment with an anti-TNF agent or a nonbiologic DMARD. We categorized patients into 4 mutually exclusive groups based on DMARD use: <i>(i)</i> anti-TNF agent with or without another DMARD (n=6824); <i>(ii)</i> cyclosporine (CSA) without an anti-TNF agent or HCQ (n=1084); <i>(iii)</i> HCQ without an anti-TNF agent or CSA (n=27,033); and <i>(iv)</i> other nonbiologic DMARD without an anti-TNF agent, CSA, or HCQ (n=50,048), hereafter referred to as the reference group.The incidence rates of DM per 1000 person-years were 8.3 for users of anti-TNFs, 13.3 for users of cyclosporine (CSA), 8.4 for users of HCQ, and 8.1 for users of other nonbiologic DMARDs. Compared with users of nonbiologic DMARDs, the multivariate adjusted hazard ratios (aHRs) for DM were significantly lower for users of anti-TNFs with HCQ (aHR: 0.49, 95% CI: 0.36–0.66) and those who used HCQ (aHR: 0.70, 95% CI: 0.63–0.78), but not in those who used anti-TNFs without HCQ (aHR: 1.23, 95% CI: 0.94–1.60) or CSA (aHR: 1.14, 95% CI: 0.77–1.70). <h3>Conclusions</h3> The aHR for DM was lowest for RA and PSO/PSA patients who initiated treatment with an anti-TNF agent with concomitant HCQ, followed by HCQ users. <h3>References</h3> Antohe JL, Bili A, Sartorius JA, et al. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy. Arthritis Care Res (Hoboken). 2012;64:215–21. Wasko MC, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007;298:187–93. <h3>Disclosure of Interest</h3> None declared
Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results
Authors: Shaji Kumar, Jesus G. Berdeja, Ruben Niesvizky, Sagar Lonial, Jacob P. Laubach, Mehdi Hamadani, A. Keith Stewart, Parameswaran N. Hari, Vivek Roy, Robert Vescio, Jonathan L. Kaufman, Deborah Berg, Eileen Liao, Ai-Min Hui, S. Vincent Rajkumar, Paul G. Richardson
Journal: Blood (2014)
AB0301 Comparison of The Bioavailability of A Single Dose of Certolizumab Pegol Injected either by A Pre-Filled Syringe or by An Auto-Injection Device
Authors: B. Astruc, S. Watanabe, G. Parker, R. Hulhoven
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Evaluation of the pharmacokinetic (PK) properties of certolizumab pegol (CZP) has shown a linear relationship between the dose administered (intravenous and subcutaneous [sc] routes), the maximum plasma concentration (C<sub>max</sub>), and the area under the plasma concentration versus time curve (AUC).<sup>1</sup> In multiple clinical studies, the half-life (t<sub>1/2</sub>) was approximately 14 days for all CZP dosage levels tested. CZP has also been demonstrated to have good bioavailability (approximately 80%) when given sc.<sup>1</sup> <h3>Objectives</h3> To compare the bioavailability of a single CZP 400 mg dose given as 2 x 200 mg injections injected by either a pre-filled syringe (PFS) or by an auto-injection device (AI), and to investigate the safety and tolerability of both methods of administration. <h3>Methods</h3> In this open-label phase I study, healthy volunteers were randomized into two parallel groups. On Day 1, study participants were injected with either 2 x 200 mg CZP via a PFS or 2 x 200 mg CZP via an AI. CZP plasma concentrations were measured pre-dose, and post-dose at 12h, 24h and Days 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56 and 84. Safety and tolerability were assessed by recording adverse events (AEs) and serious AEs (SAEs). In addition, the tolerability of the injection was assessed by a pain visual analog scale (VAS) and an injection site reaction questionnaire. <h3>Results</h3> 98 healthy volunteers were randomized to the PFS (n=49) and AI (n=49) groups. The mean plasma CZP concentration vs time profile of the AI was similar to that of the PFS. PK parameters were similar between the two modes of administration (Table). The 90% confidence intervals (CI) for the test/reference geometric mean ratios in C<sub>max</sub>, AUC<sub>(0-t)</sub>, AUC and t<sub>1/2</sub> were all contained in the bioequivalence range of 80–125%, and no statistically significant difference was found for t<sub>max</sub> between the two modes of administration (Table). Safety assessments showed that both methods of administration were equally well-tolerated. Injections performed with the AI appeared to be less painful immediately after administration than injections given by the PFS, as well as being associated with less burning and redness. <h3>Conclusions</h3> CZP 400 mg dose is bioequivalent whether administered by AI or PFS. Overall, CZP injections were safe and well-tolerated for both administration methods. <h3>References</h3> EMA. Summary of Product Characteristics (Cimzia) 2015 <h3>Acknowledgement</h3> The authors acknowledge Costello Medical Consulting, funded by UCB Pharma, for writing and editorial assistance. <h3>Disclosure of Interest</h3> B. Astruc Employee of: Biotrial, S. Watanabe Employee of: UCB Pharma, G. Parker Employee of: UCB Pharma, R. Hulhoven Employee of: UCB Pharma
A Preliminary Report of a Phase I Study of Zevalin® Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular or Transformed Non-Hodgkin’s Lymphoma (NHL).
Authors: Andres Forero-Torres, Jatin Shah, Stephen Besh, Susan Knox, Ivana Micallef, George Wiseman, Thomas Witzig, Albert Lobuglio, Sui Shen, Michael Goris, Jeanne Connor, Ruby Meredith
Journal: Blood (2005)
Long-Term Persistence of Functionally Altered GPI-Anchor Negative T-Cell Subsets After Alemtuzumab-Based T-Cell Depleted Hematopoietic Stem Cell Transplantation.
Authors: Eva M Wagner, Aline N Lay, Timo Schmitt, Julia Hemmerling, Diana Wolff, Christoph Huber, Wolfgang Herr, Ralf G Meyer
Journal: Blood (2009)
Variants in PVT1 are Associated with Susceptibility for Hodgkin Lymphoma in Children and Adolescents: A Children’s Oncology Group Study
Authors: Amy Linabery, Seymour Grufferman, Jenny N. Poynter, Julie A. Ross, Logan G. Spector, Kara M. Kelly, William Iacono, Matthew McGue, Nathan Pankratz
Journal: Blood (2014)
Influence of the fusion gene ETV6-RUNX1 in the prognosis of the Pediatric B- Precursor Acute Lymphoblastic Leukemia
Authors: Alejandro Contento-Gonzalo, Antonio Jimenez-Velazco, Alcala-Peña Magdalena, Manuel Barrios, Katie Hurst, Dana Diaz-Canales, Soraya Lorente de uña, Jose Coin-Ruiz, Maria Elvira Gonzalez-valentin, Ana Isabel Heiniger Mazo
Journal: Blood (2011)
First Report of the Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide Maintenance: Feasibility of a National Canadian Study Based on Achievement of Minimal Residual Disease (MRD) Negativity
Authors: Donna Reece, Giovanni Piza Rodriguez, Mariela Pantoja, Christopher P. Venner, Darrell White, Julie Stakiw, Michael Sebag, Terrance Comeau, Kevin Song, Jean Roy, Leonard Minuk, Jason Tay, Vishal Kukreti, Suzanne Trudel, Anca Prica, Rodger Tiedemann, Christine Chen
Journal: Blood (2014)
Effect of Antithymocyte Globulin Dosage for Prophylactic Gvhd On Epstein-Barr Virus Reactivation and Diseases in Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Guo-pan Yu, Qifa Liu, Jing SUN, Li Xuan, Meiqing Wu, Xiaodan Liu, Dan Xu, Fan Yi Meng, Hongsheng Zhou, Fen Huang
Journal: Blood (2012)
THU0264 A Selective JAK1 Inhibitor, Filgotinib Suppresses Lymphocytic Infiltration in Salivary Gland of Non Obese Diabetic Mice via Suppression of Baff Production of Salivary Gland Epithelial Cells
Authors: J. Lee, J. Lee, S.-Y. Baek, J.H. Koh, M.-K. Chung, H. Jeon, S.H. Kim, J.H. Yoo, H. Kim, S.-K. Kwok, J.H. Ju, S.-H. Park
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Interferon (IFN) signatures are upregulated in patients with primary Sjogren9s syndrome (pSS) and interferons are considered to play a pathogenic role in pSS. Therefore, Janus kinase (JAK) which mediates interferon signaling pathway may be a good therapeutic target <h3>Objectives</h3> We set out to investigate whether a selective JAK1 inhibitor, filgotinib would ameliorate disease-related parameters in non-obese diabetic (NOD) mice, an animal model SS <h3>Methods</h3> Filgotinib (1.5mg/kg) or vehicle (saline) was intraperitoneally injected three times per week from 8 weeks after birth. Salivary flow rate (SFR) was addressed on 8, 12, 16 and 20 weeks. Histologic analysis was performed on 20 weeks. The effect of filgotinib on the expressions of B cell activating factor (BAFF) and chemokines (CXCL10 [IP-10], CXCL3 [fractalkine], CCL-2 [MCP-1]) in human salivary gland epithelial cell (SGEC) line or primary epithelial cells of patients with pSS was determined <i>in vitro</i>. <h3>Results</h3> The SFR of NOD mice in both groups decreased over time. Of note, SFRs of filgotinib-treated mice were greater than those of controls. Histologic evaluation of the salivary gland revealed that the lymphocytic infiltration of salivary gland was markedly reduced in the mice treated with filgotinib. Filgotinib suppressed STAT1 phosphorylation in IFN-treated SGECs. In addition, IFN-induced BAFF and chemokine production of SGECs or primary epithelial cells were abrogated by filgotinib treatment. <h3>Conclusions</h3> Filgotinib suppresses SFR decrease and lymphocytic infiltration of salivary glands of NOD mice by inhibiting inhibiting IFN signaling pathway, thus suppressing BAFF and chemokine production of salivary gland epithelial cells. JAK inhibition may be a novel therapeutic approach for SS. <h3>Disclosure of Interest</h3> None declared
Low Levels of Receptor Chimerism, Determined by Real-Time PCR at the Time of Granulocytic Engraftment, Predicts the Onset of Acute Graft Versus Host Disease in Transplanted Leukemic Patients
Authors: Alejandro Contento-Gonzalo, Antonio JiménezVelasco, Manuel Barrios, José Román-Gómez, Antonio P. Torres Gomez, Ana Isabel Heiniger
Journal: Blood (2008)
European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia
Authors: Jane S. Lucas, Angelo Barbato, Samuel A. Collins, Myrofora Goutaki, Laura Behan, Daan Caudri, Sharon Dell, Ernst Eber, Estelle Escudier, Robert A. Hirst, Claire Hogg, Mark Jorissen, Philipp Latzin, Marie Legendre, Margaret W. Leigh, Fabio Midulla, Kim G. Nielsen, Heymut Omran, Jean-Francois Papon, Petr Pohunek, Beatrice Redfern, David Rigau, Bernhard Rindlisbacher, Francesca Santamaria, Amelia Shoemark, Deborah Snijders, Thomy Tonia, Andrea Titieni, Woolf T. Walker, Claudius Werner, Andrew Bush, Claudia E. Kuehni
Journal: European Respiratory Journal (2016)

The diagnosis of primary ciliary dyskinesia is often confirmed with standard, albeit complex and expensive, tests. In many cases, however, the diagnosis remains difficult despite the array of sophisticated diagnostic tests. There is no "gold standard" reference test. Hence, a Task Force supported by the European Respiratory Society has developed this guideline to provide evidence-based recommendations on diagnostic testing, especially in light of new developments in such tests, and the need for robust diagnoses of patients who might enter randomised controlled trials of treatments. The guideline is based on pre-defined questions relevant for clinical care, a systematic review of the literature, and assessment of the evidence using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach. It focuses on clinical presentation, nasal nitric oxide, analysis of ciliary beat frequency and pattern by high-speed video-microscopy analysis, transmission electron microscopy, genotyping and immunofluorescence. It then used a modified Delphi survey to develop an algorithm for the use of diagnostic tests to definitively confirm and exclude the diagnosis of primary ciliary dyskinesia; and to provide advice when the diagnosis was not conclusive. Finally, this guideline proposes a set of quality criteria for future research on the validity of diagnostic methods for primary ciliary dyskinesia.
ZAP-70 Enhances Infiltration of Malignant B Lymphocytes Into the Bone Marrow by Increasing Migratory and Survival Responses to CXCR4 Stimulation
Authors: Marta Crespo, Eva Calpe, Noelia Purroy, Cecilia Carpio, Pau Abrisqueta, Carles Palacio, Josep Castellvi, Francesc Bosch
Journal: Blood (2012)
Blockade of Mir-150 Maturation by MLL-Fusion/MYC/Lin-28 Is Required for MLL-Associated Leukemia
Authors: Xi Jiang, Hao Huang, Zejuan Li, Yuanyuan Li, Xiao Wang, Sandeep Gurbuxani, Ping Chen, Chunjiang He, Dewen You, Shuodan Zhang, Jinhua Wang, Stephen Arnovitz, Abdel Elkahloun, Colles Price, Gia-Ming Hong, Haomin Ren, Rejani B. Kunjamma, Mary Beth Neilly, Richard A. Larson, Michelle M. Le Beau, Robert K. Slany, Paul P. Liu, Jun Lu, Jiwang Zhang, Chuan He, Janet D. Rowley, Jianjun Chen
Journal: Blood (2012)
Evolution of Rituximab as “Standard” Therapy in Patients (pts) with Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) in Japan: An Analysis from West-Japan Hematology/Oncology Group (West-JHOG) NHL Outcomes Project.
Authors: Yuichiro Nawa, Keitaro Matsuo, Kazuki Sunami, Kazuto Togitani, Hidetaka Takimoto, Hisakazu Nishimori, Yoshinobu Maeda, Yasushi Hiramatsu, Toru Kiguchi, Tomofumi Yano, Hiromichi Yamane, Takayuki Tabayashi, Makoto Takeuchi, Masanori Makita, Nobuo Sezaki, Kazuma Ikeda, Fumihiko Ishimaru, Katsuji Shinagawa, Masamichi Hara, Mitsune Tanimoto
Journal: Blood (2006)
Gene Expression Profiling (GEP) of Myeloma (MM) Cells To Predict Attainment (near) Complete Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed MM.
Authors: Carolina Terragna, M. Renzulli, D. Remondini, E. Tagliafico, E. Roncaglia, P. Tosi, E. Zamagni, P. Tacchetti, G. Perrone, M. Ceccolini, Giovanni Martinelli, M. Baccarani, M. Cavo
Journal: Blood (2006)